Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies
Durham, North Carolina, June 30, 2023 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARIs), today announced that it has raised $5 million dollars to advance its inhaled antibody platform for potential treatment of acute respiratory infections. The Series A was co-led by JSR Life Sciences and Life Science Angels.
Inhalon believes delivery of its antibodies directly to the site of infection in the lung will be a highly effective method for treating ARIs. Additionally, the company’s antibodies are designed to be self-administered by patients using a handheld portable nebulizer, making them easy to administer. Proceeds from the financing will support Inhalon Biopharma in conducting clinical trials to demonstrate the value of this delivery approach in treating ARIs.
“Inhalon Biopharma’s inhaled antibody platform has the potential to dramatically improve the treatment of acute respiratory infections such as respiratory syncytial virus (RSV), influenza, SARS, and other transmissible viral infections,” said John Whelan, president and chief executive officer, Inhalon Biopharma. “We look forward to demonstrating the clinical effectiveness of antibodies we develop on this platform in the coming years.”
About Inhalon Biopharma
Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC.